塞德斯醫療 CLDX 深 滬
等待開盤 03-26 09:30:00 美东时间
31.68
+0.490
+1.57%
華盛通- 最 高32.44
- 今 開31.77
- 成交量 65.70万股
- 最 低 31.39
- 昨 收 31.19
- 總市值 21.09亿
- 52周最高 34.52
- 市盈率 靜 --
- 換手率 0.99%
- 52周最低 14.40
- 委 比 -32.34%
- 總股本 6656.63万
- 歷史最高 582.60
- 量 比 0.44
- 振 幅 3.37%
- 歷史最低 1.50
- 每 手 1
- 風險率 3.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
Stifel Reiterates Buy on Celldex Therapeutics, Raises Price Target to $68
Stifel analyst Alex Thompson reiterates Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $58 to $68.
02-26 22:19
财报速睇 | 塞德斯医疗 2025财年年度营收0.02亿美元，同比下降71.4%；归母净利润亏损2.59亿美元，同比亏损扩大63.9%
华盛资讯2月26日讯，塞德斯医疗公布2025财年年度业绩，公司年度营收0.02亿美元，同比下降71.4%，归母净利润亏损2.59亿美元，同比亏损扩大63.9%。
02-26 09:09
Celldex Therapeutics Q4 EPS $(1.22) Misses $(1.00) Estimate, Sales $100.000K Miss $1.477M Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.00) by 21.88 percent. This is a 71.83 percent decrease over losses of $(0.71) per share
02-26 05:47
财报速睇 | 塞德斯医疗 2025财年Q4营收0.00亿美元，同比下降89.7%；归母净利润亏损0.81亿美元，同比亏损扩大72.7%
华盛资讯2月26日讯，塞德斯医疗公布2025财年Q4业绩，公司Q4营收0.00亿美元，同比下降89.7%，归母净利润亏损0.81亿美元，同比亏损扩大72.7%。
02-26 05:17
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile
Celldex has announced that data from its Phase 2 clinical trials of barzolvolimab for chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) have been accepted for presentation at the 2026 AAAAI Annual Meeting in Philadelphia. The presentations highlight improvements in urticaria control and quality of life, as well as rapid symptom relief upon retreatment. Barzolvolimab, a novel monoclonal antibody target...
02-23 13:01
塞德斯医疗公布2026年研发规划，股价近期震荡下行
经济观察网 塞德斯医疗于2026年2月12日公布2026年关键研发规划，Barzol药物针对慢性自发性荨麻疹（CSU）的III期临床试验预计于2026年7月完成...
02-15 04:08
Celldex Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil
Celldex Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil Celldex Therapeutics Inc. wird am 11. Februar 2026 um 15:30 Uhr ET am Guggenheim Emerging Outlook: Biotech Summit 2026 teilnehmen, am 4. März 2026 um 9:10 Uhr ET an der TD Cowen 46th Annual Health Care Conference und a
02-09 21:01
Celldex to Present at Upcoming Investor Conferences
Celldex announced that its management will participate in fireside chats at three upcoming investor conferences: the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, TD Cowen 46th Annual Health Care Conference on March 4, and the Leerink Global Healthcare Conference on March 10. Live webcasts and 90-day replay access will be available on the "Events & Presentations" page of Celldex's Investors section. Celldex focuses on advancing...
02-09 13:01
